MANGOCEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| For The Three Months | For The Three Months | For The Six Months | For The Six Months | |
|---|---|---|---|---|
| Ended | Ended | Ended | Ended | |
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |
| Revenues | ||||
| Revenues | $68,757 | $168,109 | $136,621 | $277,415 |
| Cost of revenues | 10,437 | 18,815 | 18,655 | 43,552 |
| Cost of revenues - related party | 14,105 | 59,346 | 44,750 | 81,851 |
| Gross profit | 44,215 | 89,948 | 73,216 | 152,012 |
| Operating expenses | ||||
| General and administrative expenses | 256,095 | 1,245,360 | 1,322,668 | 2,787,804 |
| Salary and benefits | 427,298 | 628,343 | 774,158 | 1,254,941 |
| Advertising and marketing | 301,445 | 258,295 | 395,518 | 540,027 |
| Investor relations | - | 106,000 | - | 1,525,000 |
| Stock based compensation | 92,417 | 3,120,445 | 1,740,238 | 4,165,924 |
| Total operating expenses | 1,077,255 | 5,358,443 | 4,232,582 | 10,273,696 |
| Loss from operations | (1,033,040) | (5,268,495) | (4,159,366) | (10,121,684) |
| Other (income) expense | ||||
| Interest expense | - | 21,700 | - | 8,000 |
| Interest expense - amortization of intangible assets | 279,891 | - | 556,706 | - |
| Loss from settlement | - | 125,625 | - | 125,625 |
| Total other expense | 279,891 | 147,325 | 556,706 | 133,625 |
| Loss before income taxes | (1,312,931) | (5,415,820) | (4,716,072) | (10,255,309) |
| Income taxes | - | - | - | |
| Net loss | (1,312,931) | (5,415,820) | (4,716,072) | (10,255,309) |
| Net income (loss) attributed to non-controlling interest | (278) | (2) | (269) | (100) |
| Net loss attributed to Mangoceuticals, Inc. | (1,312,653) | (5,415,818) | (4,715,803) | (10,255,209) |
| Basic and diluted loss per share | ||||
| Basic and diluted loss per share | $(0.09) | $(0.57) | $(0.32) | $(1.49) |
| Weighted average number of shares outstanding | ||||
| Basic and diluted | 17,119,619 | 9,983,376 | 16,802,376 | 7,282,955 |
| Basic and diluted loss per share calculation | ||||
| Preferred stock dividend requirements | 294,000 | 294,000 | 588,000 | 588,000 |
| Net loss attributed to Mangoceuticals, Inc. common stockholders | $(1,606,653) | $(5,709,818) | $(5,303,803) | $(10,843,209) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.